1. Home
  2. BBY vs RPRX Comparison

BBY vs RPRX Comparison

Compare BBY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Best Buy Co. Inc.

BBY

Best Buy Co. Inc.

HOLD

Current Price

$74.02

Market Cap

15.6B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$39.70

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBY
RPRX
Founded
1966
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BBY
RPRX
Price
$74.02
$39.70
Analyst Decision
Buy
Strong Buy
Analyst Count
19
3
Target Price
$84.24
$46.00
AVG Volume (30 Days)
4.1M
4.3M
Earning Date
11-25-2025
11-05-2025
Dividend Yield
5.12%
2.21%
EPS Growth
N/A
N/A
EPS
3.02
1.75
Revenue
$41,825,000,000.00
$2,349,844,000.00
Revenue This Year
$1.77
$37.13
Revenue Next Year
$1.32
$1.48
P/E Ratio
$24.54
$22.68
Revenue Growth
N/A
3.70
52 Week Low
$54.99
$24.05
52 Week High
$91.68
$41.24

Technical Indicators

Market Signals
Indicator
BBY
RPRX
Relative Strength Index (RSI) 40.86 57.50
Support Level $74.24 $39.24
Resistance Level $83.67 $40.50
Average True Range (ATR) 2.59 0.91
MACD -0.30 -0.08
Stochastic Oscillator 11.07 76.02

Price Performance

Historical Comparison
BBY
RPRX

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: